Medivir appoints Malene Jensen as VP Clinical Development

Rhea-AI Summary

Medivir AB has appointed Malene Jensen as Vice President Clinical Development, effective no later than October 1, 2021. Jensen brings 15 years of experience in Clinical Development, previously at AstraZeneca and Sedana Medical. She will focus on the clinical trials for MIV-818, a drug aimed at liver cancer treatment, which is a priority for Medivir.

The company's strategic direction includes addressing high unmet medical needs in cancer therapy and enhancing patient outcomes.

Positive

• Appointment of Malene Jensen brings extensive clinical development experience.
• Focus on clinical trials for MIV-818, targeting liver cancer treatment.

Negative

• None.

STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team.

Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm.

"We are pleased to welcome Malene and her vast clinical development experience to Medivir. Malene will focus on the clinical trials with our key program, MIV-818, and she will be a valuable member of the management team," said Magnus Christensen, Interim CEO of Medivir.

For additional information, please contact
Magnus Christensen
Interim CEO and CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com 

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-appoints-malene-jensen-as-vp-clinical-development,c3378301

The following files are available for download:

https://mb.cision.com/Main/652/3378301/1439725.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/medivir-appoints-malene-jensen-as-vp-clinical-development-301324486.html

SOURCE Medivir

FAQ

Who is Malene Jensen, and what is her role at Medivir?

Malene Jensen has been appointed Vice President Clinical Development at Medivir, effective by October 1, 2021.

What is the focus of Malene Jensen's work at Medivir?

Malene Jensen will concentrate on the clinical trials for MIV-818, a drug aimed at treating liver cancer.

What is MIV-818?

MIV-818 is a pro-drug developed by Medivir designed to selectively target liver cancer cells while minimizing side effects.

When will Malene Jensen officially start her role at Medivir?

Malene Jensen is set to start her role no later than October 1, 2021.

What experience does Malene Jensen bring to Medivir?

She has 15 years of leadership experience in Clinical Development from companies like AstraZeneca and Sedana Medical.